Recommendation 5: Clinicians should provide patients with evidence-based information on low back pain with regard to their expected course, advise patients to remain active, and provide information about effective self-care options (strong recommendation, moderate-quality evidence).
Clinicians should inform all patients of the generally favorable prognosis of acute low back pain with or without sciatica, including a high likelihood for substantial improvement in the first month [6, 40]. Clinicians should explain that early, routine imaging and other tests usually cannot identify a precise cause, do not improve patient outcomes, and incur additional expenses. Clinicians should also review indications for reassessment and diagnostic testing (see recommendations 1 and 4). General advice on self-management for nonspecific low back pain should include recommendations to remain active, which is more effective than resting in bed for patients with acute or subacute low back pain [65, 66]. If patients require periods of bed rest to relieve severe symptoms, they should be encouraged to return to normal activities as soon as possible. Self-care education books (see Glossary) based on evidence-based guidelines, such as The Back Book , are recommended because they are an inexpensive and efficient method for supplementing clinician-provided back information and advice and are similar or only slightly inferior in effectiveness to such costlier interventions as supervised exercise therapy, acupuncture (see Glossary), massage (see Glossary), and spinal manipulation (see Glossary) [65, 66, 68–70]. Other methods for providing self-care education, such as e-mail discussion groups, layperson-led groups, videos, and group classes, are not as well studied.
Factors to consider when giving advice about activity limitations to workers with low back pain are the patient's age and general health and the physical demands of required job tasks. However, evidence is insufficient to guide specific recommendations about the utility of modified work for facilitating return to work . For worker's compensation claims, clinicians should refer to specific regulations for their area of practice, as rules vary substantially from state to state. Brief individualized educational interventions (defined as a detailed clinical examination and advice, typically lasting several hours over 1 to 2 sessions) (see Glossary) can reduce sick leave in workers with subacute low back pain [72–74].
Application of heat by heating pads or heated blankets is a self-care option (see Glossary) for short-term relief of acute low back pain . In patients with chronic low back pain, firm mattresses are less likely than a medium-firm mattress to lead to improvement . There is insufficient evidence to recommend lumbar supports  or the application of cold packs  as self-care options.
Although evidence is insufficient to guide specific self-management recommendations for patients with acute radiculopathy or spinal stenosis, some trials enrolled mixed populations of patients with and without sciatica, suggesting that applying principles similar to those used for nonspecific low back pain is a reasonable approach (see also recommendation 4).
Recommendation 6: For patients with low back pain, clinicians should consider the use of medications with proven benefits in conjunction with back care information and self-care. Clinicians should assess severity of baseline pain and functional deficits, potential benefits, risks, and relative lack of long-term efficacy and safety data before initiating therapy (strong recommendation, moderate-quality evidence). For most patients, first-line medication options are acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs).
Medications in several classes have been shown to have moderate, primarily short-term benefits for patients with low back pain. Each class of medication is associated with unique trade-offs involving benefits, risks, and costs. For example, acetaminophen is a slightly weaker analgesic than NSAIDs (<10 points on a 100-point visual analogue pain scale) [78–82] but is a reasonable first-line option for treatment of acute or chronic low back pain because of a more favorable safety profile and low cost [79, 82–84]. However, acetaminophen is associated with asymptomatic elevations of aminotransferase levels at dosages of 4 g/d (the upper limit of U.S. Food and Drug Administration–[FDA] approved dosing) even in healthy adults, although the clinical significance of these findings are uncertain . Nonselective NSAIDs are more effective for pain relief than is acetaminophen , but they are associated with well-known gastrointestinal and renovascular risks . In addition, there is an association between exposure to cyclooxygenase-2–selective or most nonselective NSAIDs and increased risk for myocardial infarction . Clinicians should therefore assess cardiovascular and gastrointestinal risk factors before prescribing NSAIDs and recommend the lowest effective doses for the shortest periods necessary. Clinicians should also remain alert for new evidence about which NSAIDs are safest and consider strategies for minimizing adverse events in higher-risk patients who are prescribed NSAIDs (such as co-administration with a proton-pump inhibitor) . There is insufficient evidence to recommend for or against analgesic doses of aspirin in patients with low back pain .
Opioid analgesics or tramadol are an option when used judiciously in patients with acute or chronic low back pain who have severe, disabling pain that is not controlled (or is unlikely to be controlled) with acetaminophen and NSAIDs. Because of substantial risks, including aberrant drug-related behaviors with long-term use in patients vulnerable or potentially vulnerable to abuse or addiction, potential benefits and harms of opioid analgesics should be carefully weighed before starting therapy [89–91]. Failure to respond to a time-limited course of opioids should lead to reassessment and consideration of alternative therapies or referral for further evaluation [92–94]. Evidence is insufficient to recommend one opioid over another .
The Glossary term skeletal muscle relaxants refers to a diverse group of medications, some with unclear mechanisms of action, grouped together because they carry FDA-approved indications for treatment of musculoskeletal conditions or spasticity. Although the antispasticity drug tizanidine has been well studied for low back pain, there is little evidence for the efficacy of baclofen or dantrolene, the other FDA-approved drugs for the treatment of spasticity . Other medications in the skeletal muscle relaxant class are an option for short-term relief of acute low back pain, but all are associated with central nervous system adverse effects (primarily sedation). There is no compelling evidence that skeletal muscle relaxants differ in efficacy or safety [96, 97]. Because skeletal muscle relaxants are not pharmacologically related, however, risk–benefit profiles could in theory vary substantially. For example, carisoprodol is metabolized to meprobamate (a medication associated with risks for abuse and overdose), dantrolene carries a black box warning for potentially fatal hepatotoxicity, and both tizanidine and chlorzoxazone are associated with hepatotoxicity that is generally reversible and usually not serious.
Tricyclic antidepressants are an option for pain relief in patients with chronic low back pain and no contraindications to this class of medications [98, 99]. Antidepressants in the selective serotonin reuptake inhibitor class and trazodone have not been shown to be effective for low back pain, and serotonin–norepineprhine reuptake inhibitors (duloxetine and venlafaxine) have not yet been evaluated for low back pain. Clinicians should bear in mind, however, that depression is common in patients with chronic low back pain and should be assessed and treated appropriately .
Gabapentin is associated with small, short-term benefits in patients with radiculopathy [101, 102] and has not been directly compared with other medications or treatments. There is insufficient evidence to recommend for or against other antiepileptic drugs for back pain with or without radiculopathy. For acute or chronic low back pain, benzodiazepines seem similarly effective to skeletal muscle relaxants for short-term pain relief  but are also associated with risks for abuse, addiction, and tolerance. Neither benzodiazepines nor gabapentin are FDA-approved for treatment of low back pain (with or without radiculopathy). If a benzodiazepine is used, a time-limited course of therapy is recommended.
Herbal therapies, such as devil's claw, willow bark, and capsicum, seem to be safe options for acute exacerbations of chronic low back pain, but benefits range from small to moderate. In addition, many of the published trials were led by the same investigator, which could limit applicability of findings to other settings .
Systemic corticosteroids are not recommended for treatment of low back pain with or without sciatica, because they have not been shown to be more effective than placebo [104–107].
Most medication trials evaluated patients with nonspecific low back pain or mixed populations with and without sciatica. There is little evidence to guide specific recommendations for medications (other than gabapentin) for patients with sciatica or spinal stenosis. Evidence is also limited on the benefits and risks associated with long-term use of medications for low back pain. Therefore, extended courses of medications should generally be reserved for patients clearly showing continued benefits from therapy without major adverse events.
Recommendation 7: For patients who do not improve with self-care options, clinicians should consider the addition of nonpharmacologic therapy with proven benefits—for acute low back pain, spinal manipulation; for chronic or subacute low back pain, intensive interdisciplinary rehabilitation, exercise therapy, acupuncture, massage therapy, spinal manipulation, yoga, cognitive-behavioral therapy, or progressive relaxation (weak recommendation, moderate-quality evidence).
For acute low back pain (duration <4 weeks), spinal manipulation administered by providers with appropriate training is associated with small to moderate short-term benefits . Supervised exercise therapy and home exercise regimens are not effective for acute low back pain , and the optimal time to start exercise therapy after the onset of symptoms is unclear. Other guidelines suggest starting exercise after 2 to 6 weeks, but these recommendations seem to be based on poor-quality evidence [25, 110]. Other nonpharmacologic treatments have not been proven to be effective for acute low back pain.
For subacute (duration >4 to 8 weeks) low back pain, intensive interdisciplinary rehabilitation (defined as an intervention that includes a physician consultation coordinated with a psychological, physical therapy, social, or vocational intervention) (see Glossary) is moderately effective , and functional restoration (see Glossary) with a cognitive-behavioral component reduces work absenteeism due to low back pain in occupational settings . There is little evidence on effectiveness of other treatments specifically for subacute low back pain . However, many trials enrolled mixed populations of patients with chronic and subacute symptoms, suggesting that results may reasonably be applied to both situations.
For chronic low back pain, moderately effective nonpharmacologic therapies include acupuncture [114, 115], exercise therapy , massage therapy , Viniyoga-style yoga (see Glossary) , cognitive-behavioral therapy or progressive relaxation (see Glossary) [117, 118], spinal manipulation , and intensive interdisciplinary rehabilitation , although the level of supporting evidence for different therapies varies from fair to good (Appendix Table 6). In meta-regression analyses, exercise programs that incorporate individual tailoring, supervision, stretching, and strengthening are associated with the best outcomes . The evidence is insufficient to conclude that benefits of manipulation vary according to the profession of the manipulator (chiropractor vs. other clinician trained in manipulation) or according to presence or absence of radiating pain . With the exception of continuous or intermittent traction (see Glossary), which has not been shown to be effective in patients with sciatica [120–122], few trials have evaluated the effectiveness of treatments specifically in patients with radicular pain  or symptoms of spinal stenosis. In addition, there is insufficient evidence to recommend any specific treatment as first-line therapy. Patient expectations of benefit from a treatment should be considered in choosing interventions because they seem to influence outcomes . Some interventions (such as intensive interdisciplinary rehabilitation) may not be available in all settings, and costs for similarly effective interventions can vary substantially. There is insufficient evidence to recommend the use of decision tools or other methods for tailoring therapy in primary care, although initial data are promising [124–126].
Transcutaneous electrical nerve stimulation (see Glossary) and intermittent or continuous traction (in patients with or without sciatica) have not been proven effective for chronic low back pain (Appendix Table 6). Acupressure (see Glossary), neuroreflexotherapy (see Glossary), and spa therapy (see Glossary) have not been studied in the United States, and percutaneous electrical nerve stimulation (see Glossary) is not widely available. There is insufficient evidence to recommend interferential therapy (see Glossary), low-level laser therapy (see Glossary), shortwave diathermy (see Glossary), or ultrasonography. Evidence is inconsistent on back schools (see Glossary), which have primarily been evaluated in occupational settings, with some trials showing small, short-term benefits .
It may be appropriate to consider consultation with a back specialist when patients with nonspecific low back pain do not respond to standard noninvasive therapies. However, there is insufficient evidence to guide specific recommendations on the timing of or indications for referral, and expertise in management of low back pain varies substantially among clinicians from different disciplines (including primary care providers). In general, decisions about consultation should be individualized and based on assessments of patient symptoms and response to interventions, the experience and training of the primary care clinician, and the availability of specialists with relevant expertise. In considering referral for possible surgery or other invasive interventions, other published guidelines suggest referring patients with nonspecific low back pain after a minimum of 3 months  to 2 years  of failed nonsurgical interventions. Although specific suggestions about timing of referral are somewhat arbitrary, one factor to consider is that trials of surgery for nonspecific low back pain included only patients with at least 1 year of symptoms [129–131]. Other recommendations for invasive interventions are addressed in a separate guideline from the APS .